The Use of Low Molecular Weight Heparin Among COVID-19 Patients in Udayana University Hospital, Bali




COVID-19; Low Molecular Weight Heparin; Prophylaxis; Treatment.


Experts have speculated the potential of heparin administration as COVID-19 treatment modality, although scientific research regarding its effectivity, recommended dosage, and period are still minimal. This study aims to explore the capacity of LMWH as a medicament for COVID-19, in effort to provide scientific reference for further development of COVID-19 possible choice of treatment or medicament. A retrospective study was conducted in Udayana University Hospital, Bali, Indonesia. Data were sourced from laboratory-confirmed COVID-19 patients medical records during March 25 to July 31, 2020. Clinical, laboratory, treatment and use of LMWH data were reviewed and statistically processed.  42 patients we found Use of LMWH. The patient categorizes from moderate to severe COVID-19. 31 patients use of LMWH for prophylaxis and 11 patients use of LMWH for treatment. 7 patients were death in the hospital, and the other was survived. LMWH elevates coagulation dysfunction in COVID-19 patients. We believe that beneficial effects of LMWH as prophylaxis or treatment in COVID-19 patients.


Ayerbe, L., Risco, C., & Ayis, S. (2020). The association between treatment with heparin and survival in patients with Covid-19. Journal of Thrombosis and Thrombolysis, 50(2), 298–301.

Dahlan, S. (2013). Statistik Untuk Kedokteran dan Kesehatan. Penerbit Salemba.

Hendriks, S. A. (2017). Understanding The Clinical Course of Dementia.

Hosseini, A., & Bahramnezhad, F. (2020). Pulmonary embolism in patients with COVID-19 and its treatment based on low-molecular-weight heparin. Sao Paulo Medical Journal, 138(4), 349–351.

Liu, Y., Lee, J. M., & Lee, C. (2020). The challenges and opportunities of a global health crisis: the management and business implications of COVID-19 from an Asian perspective. Asian Business and Management, 19(3), 277–297.

Paolisso, P., Bergamaschi, L., D’Angelo, E. C., Donati, F., Giannella, M., Tedeschi, S., Pascale, R., Bartoletti, M., Tesini, G., Biffi, M., Cosmi, B., Pizzi, C., Viale, P., & Galié, N. (2020). Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients. Frontiers in Pharmacology, 11.

Tang, N., Li, D., Wang, X., & Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis, 18(4), 844–847.

Zhang, J., Meng, G., Li, W., Shi, B., Dong, H., Su, Z., Huang, Q., & Gao, P. (2020). Relationship of chest CT score with clinical characteristics of 108 patients hospitalized with COVID-19 in Wuhan, China. Respiratory Research, 21(1).

Zhang, L., Dong, L., Ming, L., Wei, M., Li, J., Hu, R., & Yang, J. (2020). Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection during late pregnancy: a report of 18 patients from Wuhan, China. BMC Pregnancy and Childbirth, 20(1).




How to Cite

HARKITASARI, S.; PURNAMASIDHI, C. A. W.; RENA, N. M. R. A.; SUKMAWATI, N. M. D. D.; SOMIA, I. K. A. The Use of Low Molecular Weight Heparin Among COVID-19 Patients in Udayana University Hospital, Bali. Research, Society and Development, [S. l.], v. 11, n. 10, p. e375111031821, 2022. DOI: 10.33448/rsd-v11i10.31821. Disponível em: Acesso em: 4 oct. 2022.



Health Sciences